Skip to Main Content

Paper Details

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Blood Cancer Discov
4
2023
AML, Acute Myeloid Leukemia, BCL2, JAK1/2, Ven, Venetoclax, acute myeloid leukemia, azacytidine, patient, patients, ruxolitinib, tumor, tumor cell, venetoclax
Antineoplastic Agents, Azacitidine, Humans, Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2
Author NameAffiliation
Christopher A EideKnight Cancer Institute, Oregon Health and Science University
Stephen E KurtzKnight Cancer Institute, Oregon Health and Science University
Stephen E KurtzKnight Cancer Institute, Oregon Health and Science University
Andy KaempfKnight Cancer Institute, Oregon Health and Science University
Nicola LongKnight Cancer Institute, Oregon Health and Science University
Sunil Kumar JoshiKnight Cancer Institute, Oregon Health and Science University
Tamilla NechiporukKnight Cancer Institute, Oregon Health and Science University
Ariane HuangKnight Cancer Institute, Oregon Health and Science University
Charles A DibbKnight Cancer Institute, Oregon Health and Science University
Akosha TaylorKnight Cancer Institute, Oregon Health and Science University
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health and Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health and Science University
Jessica MinnierKnight Cancer Institute, Oregon Health and Science University
Curtis A LachowiezKnight Cancer Institute, Oregon Health and Science University
Jennifer N SaultzKnight Cancer Institute, Oregon Health and Science University
Ronan SwordsKnight Cancer Institute, Oregon Health and Science University
Anupriya AgarwalKnight Cancer Institute, Oregon Health and Science University
Bill H ChangKnight Cancer Institute, Doernbecher Children's Hospital, Oregon Health and Science University
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
  • 1 - 22

Datasets